Abstract
A Phase 2 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX005 in Patients with, or at Risk of, Manifest Huntington’s Disease (HD) (S32.009)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have